Single-cell map shows how pancreatic cancer clones evolve to outsmart treatment

Pancreatic cancer has long been one of medicine’s most stubborn adversaries, a disease that shrugs off chemotherapy, resists immunotherapy, and claims the lives of more than 85 percent of patients within five years of diagnosis. Now, a landmark single-cell study led by researchers at UC San Diego Moores Cancer Center and New York University has revealed, in unprecedented detail, why this cancer is so difficult to defeat: it is not one disease behaving uniformly, but a shifting population of genetically distinct clones that continuously reshape their DNA to survive. The research, published in the journal Nature Genetics, analyzed the genetic activity of 443,451 individual cells drawn from 62 tumors removed from 59 patients with pancreatic ductal adenocarcinoma, the most common and deadliest form of pancreatic cancer. The resulting picture is one of relentless, parallel evolution unfolding inside a single tumor, with different clones taking on different identities, exploiting different survival strategies, and interacting with their surroundings in distinct ways.

Traditionally, tumor analysis has been performed in bulk, measuring average increases and decreases in gene activity across large populations of cells. That approach, while useful, effectively blurs the individual stories of the cells within a tumor, much as a crowd photograph obscures the faces of the people in it. The new study abandoned that averaging. By sequencing genetic activity cell by cell, the researchers could identify clones, clusters of tumor cells sharing a similar genetic makeup, and trace how each behaves differently within the same tumor. Some clones had evolved mechanisms to resist therapy, while others had acquired the capacity to spread rapidly to distant organs. The findings suggest that this ongoing reshaping of the cancer cells’ DNA is the engine driving both treatment resistance and metastasis, the two processes that make pancreatic ductal adenocarcinoma so lethal.

“Pancreatic cancer is one of the most aggressive human malignancies, with a dismal survival rate and very few resources and tools to combat it,” said Diane Simeone, MD, director of UC San Diego Moores Cancer Center and co-senior author of the study. “Our work shows that within a single tumor, different clones are evolving in parallel, taking on different identities and interacting with the immune and stromal landscape in distinct ways. That heterogeneity is why the disease is so hard to treat, because every tumor is unique.” Simeone, who is also a professor of surgery at UC San Diego School of Medicine, emphasized that this clonal diversity is not merely an obstacle but also an opportunity, because each distinct evolutionary path a tumor takes may expose vulnerabilities that precisely targeted therapies could exploit.

The study’s co-senior author, Aristotelis Tsirigos, PhD, professor of medicine and pathology at NYU Grossman School of Medicine and co-director of the Division of Precision Medicine, described the work as the most granular view of pancreatic ductal adenocarcinoma produced to date. “Our study provides the most granular view to date of pancreatic ductal adenocarcinoma, revealing how ongoing genetic reshaping drives tumor evolution over the course of disease,” Tsirigos said. That granularity matters because pancreatic tumors are not static targets. A biopsy taken at diagnosis captures only a snapshot of a tumor that is actively changing, and therapies designed against that snapshot may fail as the tumor’s dominant clones shift and adapt under the pressure of treatment.

One of the study’s most consequential findings concerns the long-standing practice of classifying pancreatic tumors into two molecular subtypes. Earlier bulk analyses had separated pancreatic cancer cells into a less aggressive “classical” type and a more aggressive “basal” type, but prior research had never satisfactorily explained how cancer cells move between these states. The new single-cell data show that genetic reconfiguration within a tumor enables cancer cells to transition between subtypes, effectively allowing a tumor to switch its own personality. A tumor that begins as a classical-type cancer can, through the evolution of its clones, acquire basal characteristics associated with rapid growth and therapy resistance, or harbor both populations simultaneously, presenting clinicians with two biologically distinct diseases inside a single mass.

The researchers also pinpointed specific genetic changes that emerge during this evolution. Among the most striking was increased activity of the MYC gene, a well-established driver of pancreatic cancer, within the aggressive basal tumor cell populations. MYC is a transcription factor, a protein that regulates the expression of many other genes, and its heightened activity in basal clones appears to help lock cells into their aggressive identity. In a series of follow-up experiments, the team showed that blocking MYC activity did something remarkable: it reverted the cells to the less aggressive classical form and exposed them to more immune cells, potentially making the tumor more vulnerable to immune attack. That observation suggests a tantalizing therapeutic strategy, in which suppressing a single driver gene could strip a tumor of its aggressive armor and simultaneously open the door for the patient’s own immune system to recognize and destroy it.

The study also shed light on why immunotherapy, which has transformed the treatment of many other cancers, has largely failed against pancreatic cancer. In some of the tumor clones, the researchers found elevated activity of the TIGIT gene, which produces proteins that help cancer cells evade immune detection. In those same clonal cells, the activity of the PD-1 gene was suppressed. This combination is significant because the most widely used immunotherapies, known as checkpoint inhibitors, work by blocking PD-1 and related pathways to unleash immune cells against tumors. If a tumor’s clones do not rely on PD-1 in the first place, and instead deploy alternative cloaking mechanisms such as TIGIT, then PD-1-targeting drugs have little to disengage. The finding may finally explain, at the level of individual clones, why checkpoint inhibitors so rarely produce benefit in pancreatic ductal adenocarcinoma, and it points toward alternative immune targets that future therapies could pursue.

“Clonal heterogeneity is part of why pancreatic cancer is so difficult to treat, but it also presents us with opportunities to discover more precise and effective therapies,” said Simeone. “When different clones within the same tumor evolve in different directions, they create multiple opportunities for tumors to evade treatment. Understanding this evolution is key to designing treatments that stay ahead of the disease.” The implication for clinical practice is profound. Rather than attacking a tumor with a single agent aimed at one pathway, future treatment regimens may need to anticipate the evolutionary escape routes available to a tumor’s clones, combining drugs that target multiple identities at once or sequencing therapies in ways that prevent resistant clones from gaining the upper hand.

The research also reinforces UC San Diego’s broader leadership in pancreatic cancer science and care. Simeone additionally directs the Pancreatic Cancer Early Detection Consortium, known as PRECEDE, the largest initiative of its kind in the world, which unites more than 60 partner centers in sharing data, biospecimens, and imaging to detect pancreatic cancer at its earliest and most treatable stage. “Moores Cancer Center is redefining what’s possible in pancreatic cancer,” Simeone said. “By combining fundamental research in the lab with large-scale clinical trials and global collaboration, we’re building a research ecosystem that will help us find pancreatic cancer faster, treat it more effectively, and transform outcomes for patients.” The single-cell findings from this study could eventually feed directly into such efforts, since understanding how clones evolve may also reveal the earliest molecular changes that precede aggressive disease.

The study, titled “Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression,” was funded in part by the National Institutes of Health, including grants R01CA245005 and P30CA016087, along with a Sky Foundation Seed Award. The research team included Lidong Wang, Qi Su, Sungsik Kim, Hannah Carter and Theodore H. Welling at UC San Diego Moores Cancer Center; a large collaborative group at New York University including Despoina Kalfakakou, Daniel C. Cameron, Emily A. Kawaler, Elektra Manolakos, Xiaohong Jing, Cristina Hajdu, Dylan L. Tamayo, Yoona Shim, Amanda Ackermann, Daniel Weissinger, Rosmel Hernandez, Matthew Beier, Dacia Dimartino, Peter Meyn, Kalina Rice, Shanmugapriya Selvaraj, Cynthia Loomis, Adriana Heguy, Amanda W. Lund and Igor Dolgalev; and Motoyuki Tsuda, Hayley Zimny and Rosalie C. Sears at Oregon Health and Science University. The authors declared no competing interests. For a disease that has seen so little progress over decades, the study offers something rare: a dynamic, cell-by-cell understanding of the enemy’s playbook, and with it, a roadmap for therapies designed not merely to attack pancreatic cancer as it appears, but to stay ahead of it as it evolves.

Subject of Research: Clonal evolution and heterogeneity in pancreatic ductal adenocarcinoma revealed through single-cell analysis

Article Title: Scientists reveal how pancreatic cancer evolves to evade treatment

Article References: Scientists reveal how pancreatic cancer evolves to evade treatment. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, pancreatic ductal adenocarcinoma, single-cell analysis, clonal heterogeneity, tumor evolution, MYC, TIGIT, PD-1, immunotherapy resistance, tumor microenvironment, Nature Genetics, precision medicine